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ABSTRACT
Background: Oral administration of purified omega-3 (ω-3) PUFAs is associated with changes to the fecal microbiome.
However, it is not known whether this effect is associated with increased PUFA concentrations in the gut.
Objectives: We investigated the luminal bioavailability of oral ω-3 PUFAs (daily dose 1 g EPA and 1g DHA free fatty
acid equivalents as triglycerides in soft-gel capsules, twice daily) and changes to the gut microbiome, in the ileum.
Methods: Ileostomy fluid (IF) and blood were obtained at baseline, after first capsule dosing (median 2 h), and at a
similar time after final dosing on day 28, in 11 individuals (median age 63 y) with a temporary ileostomy. Fatty acids were
measured by LC–tandem MS. The ileal microbiome was characterized by 16S rRNA PCR and Illumina sequencing.
Results: There was a mean 6.0 ± 9.8-fold and 6.6 ± 9.6-fold increase in ileal EPA and DHA concentrations (primary
outcome), respectively, at 28 d, which was associated with increased RBC ω-3 PUFA content (P ≤ 0.05). The first oral
dose did not increase the ileal ω-3 PUFA concentration except in 4 individuals, who displayed high luminal EPA and
DHA concentrations, which reduced to concentrations similar to the overall study population at day 28, suggesting
physiological adaptation. Bacteroides, Clostridium, and Streptococcus were abundant bacterial genera in the ileum. Ileal
microbiome variability over time and between individuals was large, with no consistent change associated with acute ω-3
PUFA dosing. However, high concentrations of EPA and DHA in IF on day 28 were associated with higher abundance of
Bacteroides (r2 > 0.86, P < 0.05) and reduced abundance of other genera, including Actinomyces (r2 > 0.94, P < 0.05).
Conclusions: Oral administration of ω-3 PUFAs leads to increased luminal ω-3 PUFA concentrations and changes to
the microbiome, in the ileum of individuals with a temporary ileostomy. This study is registered on the ISRCTN registry
as ISRCTN14530452. J Nutr 2021;00:1–11.
Keywords: docosahexaenoic acid, eicosapentaenoic acid, ileostomy, omega-3 polyunsaturated fatty acid, small
intestine
Introduction
Omega-3 (ω-3) PUFAs are licensed for treatment of severe
hypertriglyceridemia and prevention of cardiovascular events in
high-risk individuals (1). ω-3 PUFAs are also widely used as a
nutritional supplement, either in complex “fish oil” mixtures or,
more commonly, in concentrated “nutraceutical” forms (2).
We have reported that oral administration of 4 g of a
1:1 mix of the 2 main marine-derived ω-3 PUFAs, namely
EPA (20:5ω-3) and DHA (22:6ω-3), daily for 8 wk is
associated with a reversible change in the fecal microbiome
in middle-aged volunteers (3). ω-3 PUFA use was associated
with increased abundance of SCFA-producing bacterial taxa
such as Lactobacillus, Roseburia, and Sutterella (3). Oral
administration of EPA 2 g daily reduces rectal adenoma number
and size in patients with familial adenomatous polyposis (4)
and decreases “sporadic” conventional colorectal adenoma risk
in the distal colon and rectum (5), which is consistent with
the hypothesis that anti–colorectal cancer (CRC) activity of
ω-3 PUFA is, at least in part, mediated by increased luminal
concentrations of SCFAs, the receptors for which are expressed
predominantly in the distal colon (6). Others have also now
demonstrated that ω-3 PUFA use is associated with changes to
the human fecal microbiome (7, 8).
It is not known whether changes to the gut microbiome,
which are associated with oral intake of ω-3 PUFAs, are
mediated by increased exposure of the gut microbiota to
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intestinal luminal ω-3 PUFAs. Moreover, it is not known
whether ω-3 PUFAs detected in the distal digestive tract lumen
derive directly from oral dosing or indirectly via the intestinal
mucosal surface following absorption in the proximal small
bowel and widespread tissue incorporation throughout the
body. One study has measured ω-3 PUFA recovery (as the
percentage of the oral dose) in ileostomy effluent after dosing
with a single 1000-mg fish oil capsule (containing 48 mg EPA
and 218 mg DHA) taken with water (9). This study reported
that <1% of the total ω-3 PUFAs administered were recovered
in the ileostomy effluent between 2 and 16 h after single dosing
(9). This is consistent with the current dogma that efficient
PUFA absorption occurs in the proximal small bowel, regardless
of the chemical form of the PUFAs (as free fatty acids, ethyl ester
conjugates, or triglycerides), particularly if ω-3 PUFA dosing
occurs with food (10). However, the dose of EPA and DHA
used in the Australian study (9) was far lower than those
associated with effects on the gut microbiota and colorectal
neoplasia in prior clinical studies (which have used 2–4 g
daily) (3–5, 11). Moreover, the authors did not report PUFA
concentrations in ileal effluent, which are needed to investigate
properly the interactions between PUFAs and gut bacteria in ex
vivo intestinal models.
Therefore, we studied the intestinal luminal and systemic
bioavailability of EPA and DHA in individuals with a temporary
ileostomy undergoing oral dosing with 4 g daily of a 1:1 mix of
EPA and DHA for 28 d. We compared PUFA concentrations
obtained in the distal ileum [also acting as a proxy for
proximal colonic concentrations (12)] acutely (<24 h after
the first dose) and after longer-term oral dosing (at 28 d).
We also investigated the relation between intestinal ω-3 PUFA
concentrations and changes to the luminal microbiome in the
ileum.
Methods
This study was conducted according to the Declaration of Helsinki,
and all procedures involving human subjects/patients were approved
by the Yorkshire & Humber-Leeds West Research Ethics Committee
(15/YH/0547). Written informed consent was obtained from all
subjects. The study was registered in a publicly available trials
registry (ISRCTN14530452). The intervention was not classified as
Investigational Medicinal Product by the UK Medicines and Healthcare
Products Regulatory Agency.
Human subjects
We recruited individuals, aged ≥18 y, of either sex, who had a temporary
loop ileostomy, which had been fashioned during anterior resection
for CRC ≥2 mo prior to enrolment, for whom eventual ileostomy
reversal was planned ≥2 mo later. The original eligible age threshold
was 50 y (stipulated so that the age range of participants mirrored
a population at risk of colorectal neoplasia). However, due to slow
recruitment, we amended that eligibility criterion (with Research Ethics
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no role in the design, analysis, or writing of this article. Fatty acid measurement
was supported by the Yorkshire Experimental Cancer Medicine Centre.
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FIGURE 1 Schedule of ω-3 PUFA capsules dosing and biosample
collection from patients with a temporary ileostomy. Ileostomy fluid
and blood were obtained before the first capsules were taken (visit
1) and 1–8 h after the first capsules dose (visit 2), as well as 1–8 h
after the last capsules dose (visit 3), which was after 28 d of regular
ω-3 PUFA capsule dosing. ω-3 PUFA capsules were always taken with
meals.
Committee substantial amendment) so that the lower age limit was
18 y. We excluded individuals who: 1) were using (at any time within
4 wk of recruitment) an ω-3 PUFA–containing supplement (including
cod liver oil); 2) had received any form of systemic chemotherapy or
radiotherapy in the past 4 wk; 3) had known metastatic CRC; 4) had
small bowel disease such as Crohn disease or celiac disease; 5) had
previously undergone any small bowel resection >10 cm; or 6) were
allergic to any type of seafood.
Suitable patients were screened from colorectal surgery department
records at St James’s University Hospital, Leeds, United Kingdom, and
sent a participant information leaflet. Interested individuals attended
the hospital for a detailed eligibility check and then provided written
informed consent, if appropriate.
Participants undertook 3 further study visits over a 28-d period
(Figure 1), with visit 1 coinciding with a hospital visit for routine care,
when at all possible. Open-label ω-3 PUFA capsules were issued to
patients after written informed consent was obtained.
The ω-3 PUFA intervention
Participants were instructed to take 2 soft-gel capsules (EuroCaps Ltd),
each containing 481 mg EPA-triglyceride and 481 mg DHA-triglyceride
(500 mg/g) concentrates (Incromega; Croda Ltd), twice daily with meals
for 28 d, thereby providing a daily dose of 1 g EPA free fatty acid
equivalent and 1 g DHA free fatty acid equivalent.
Study visit schedule
At visit 1, participants provided a pretreatment (baseline) ileostomy
fluid (IF) sample, in addition to a venous blood sample, prior to taking
the first dose of capsules (Figure 1). A second IF sample and blood
sample were obtained at visit 2, which occurred at a time and place (the
hospital or at home) directed by the participant, ≥1 h and ≤8 h after
taking the first ω-3 PUFA capsules dose with a meal. After 4 wk of twice-
daily dosing with oral ω-3 PUFA capsules, participants were required
to provide a final IF and blood sample at visit 3 at an identical time
(±1 h) after the last ω-3 PUFA capsules dose as the duration between
first capsule dosing and sampling at visit 2. A 24-h ileostomy output
collection was deemed to be unacceptable for participants, after taking
advice from a patient representative. Therefore, we collected data on the
frequency of stoma bag emptying over the preceding 24 h as a proxy
for the ileostomy output volume. At each visit, participants were asked
about the presence of gastrointestinal symptoms, and any other adverse
events that had occurred during the intervention period were recorded
at visit 3. The number of capsules returned at visit 3 was used as an
indicator of compliance.
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Sample collection and analysis
Venous blood was collected into 2 EDTA-containing tubes, which were
centrifuged at 800 × g for 5 min at 4◦C within 30 min of collection.
Plasma and RBCs were separated, aliquoted, and stored at −80◦C until
analysis.
IF samples were aliquoted into 2 sterile 20-mL plastic containers,
held on ice, and stored at −80◦C before analysis.
LC–tandem MS measurement of fatty acids
Ileostomy content (150 mg) was added to 3 mL distilled water and
homogenized by vortex mixing for 60 s. Lipids were extracted from 100
μL of the ileostomy homogenate as described (13). RBCs (50 μL) were
diluted 1:1 with 50 μL distilled H2O before lipid extraction. In every
sample, 4 μL of internal standard (50 μg/mL α-linolenic acid-d14) was
added (13).
Fatty acids were measured by LC–tandem MS (13). RBC ω-3 PUFA
concentrations are presented as the relative amount (percentage total
fatty acids). ω-3 PUFA concentrations in plasma and IF are reported as
the absolute concentration in micrograms per milliliter.
Measurement of IF osmolality
IF was centrifuged at 3000 × g for 10 min at room temperature to
produce a clear supernatant for measurement of osmolality by freezing
point depression osmometry using an Advanced 2020 Multi-Sample
Osmometer (Advanced Instruments).
Ileal microbiome analysis
DNA was extracted from ∼200 mg frozen IF using a modified
version of the QIAamp DNA Stool Mini Kit protocol (QIAGEN)
with bead-beating. DNA was quantified by NanoDrop spectropho-
tometry. DNA underwent PCR amplification of the V4 region of
the 16S rRNA gene and library preparation according to the Earth
Microbiome Project 16S Illumina Amplicon methodology (http://ww
w.earthmicrobiome.org) with single PCR reactions per sample [515F
(Parada) 5´-GTGYCAGCMGCCGCGGTAA-3´ and 806R (Apprill) 5´-
GGACTACNVGGGTWTCTAAT-3´]. Sequencing was performed on
an Illumina HiSeq 3000 2 × 150-bp paired end lane. Reads were
stripped of adapter sequences using Cutadapt (v1.18) (14). Initial
analysis was performed in the QIIME2 environment (v2019.10) (15).
Reads were shortened to a maximum of 145 bp, merged, denoised,
and representative sequences picked using DADA2 (16). Representative
reads were aligned to the SILVA database (release 132) using the
BLAST+ algorithm (17, 18). All taxonomy assignments were exported
to MEGAN6 for further analysis (19), which was focused on level 6
(genus) assignments.
Statistical analysis
There are no data on absolute ileal or fecal EPA and DHA
concentrations generated during oral ω-3 PUFA supplement use.
Therefore, we were unable to perform a formal sample size calculation
based on an a priori coprimary end point of the study (ileal ω-3
EPA and DHA concentrations at the end of the treatment period).
Previous studies of ω-3 PUFA RBC membrane incorporation associated
with supplementation have reported large intraindividual (4%) and
interindividual (≤12%) CVs (9, 20). Based on a mean molar percentage
plasma EPA concentration of 0.4 reflecting ileal EPA content at
baseline and the above interindividual variance (21), we calculated
that 10 participants would detect a minimum 30% increase in ileal
EPA concentration with 80% power at a 5% significance level, the
recruitment of which would be feasible in a 1-y study period with
a maximum expected recruitment rate of 10% for an experimental
intervention study in patients undergoing 2-stage cancer surgery (102
patients underwent temporary ileostomy formation at St James’s
University Hospital during June 2014 to May 2015). The predicted
sample size was larger than the only previous clinical study of ileal ω-3
PUFA content (9).
Given the small size of this human intervention study, all other
analyses (including relative ω-3 PUFA concentrations in RBC mem-
branes, other ileal fluid measurements, and ileal microbiome analysis)
FIGURE 2 Participant flow diagram. Eight individuals completed the
study per protocol.
were classified as exploratory with hypothesis testing using α = 0.05,
acknowledging the increased risk of type I statistical error.
Statistical analysis and graphical representation of the PUFA data
was performed using GraphPad Prism version 8 (GraphPad Software,
Inc) and SPSS version 26 (IBM, Inc). Longitudinal intraindividual data
were compared using a 2-sided paired Student t test. Student unpaired
t test was used to compare values between subgroups of participants,
including sensitivity analysis of individuals with and without an early
peak in ileal EPA and DHA concentration. Nonparametric tests (Mann–
Whitney U test and Wilcoxon signed-rank test) were also used for
unpaired and paired group analyses, for data with a nonnormal
distribution (Kolmogorov–Smirnov normality test; P < 0.05). The
Spearman rank correlation test was used to test the relation between
ω-3 PUFA concentrations and timing of sampling. In all cases, a P
value <0.05 was deemed statistically significant.
Statistical analysis of the ileal microbiome data was performed
using the R package (22). β Diversity between visit samples and across
participants was tested using the Adonis permutational multivariate
ANOVA (PERMANOVA) test. Ileal microbiome (Pearson) correlation
analyses were all corrected for multiple comparisons using the
Benjamini–Hochberg false discovery rate procedure.
Results
Eleven individuals with a temporary loop ileostomy were
recruited to the study between April 2016 and December 2018
after screening 88 patients (Figure 2). Demographic and clinical
details are presented in Table 1. Eight individuals completed the
study per protocol, thus providing complete sample sets during
ω-3 PUFA capsules dosing. One participant was withdrawn
from the study after visit 2 (Figure 2) when it was realized that
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TABLE 1 Participant characteristics1
Age, y 63 (42–81)
Sex (male:female) 8:3
Duration of temporary ileostomy use before the study, mo 9 (2–18)
Frequency of ileostomy bag emptying in the last 24 h
Visit 1 3 (1–7)
Visit 3 4 (1–7)
Time between last oral dose and sample collection, h
Visit 2 2 (1–4)
Visit 3 2 (1–5)
Duration of ω-3 PUFA capsule intervention, d 28 (1–33)
Capsule compliance,2 % 100 (50–107)
1Data are the median value and range of values, unless stated otherwise.
2Capsule compliance calculated as: observed number of capsules taken [168
(number of capsules given to each participant) − number of capsules returned] ÷
expected number of capsules taken (4 × number of days taking capsules) × 100.
the individual was ineligible due to age (42 y when the eligibility
criterion was >50 y). That individual had provided consent for
the data collected to date to be used after withdrawal. One
participant stopped taking capsules on day 24 after reporting
several gastrointestinal adverse events (eructation, nausea and
abdominal discomfort), which did not improve after dose
reduction. One blood sample was not obtained at visit 2 due
to failed venipuncture. Compliance with capsule dosing was
excellent as assessed by capsule counting (Table 1). There were
no other adverse events reported during ω-3 PUFA capsules
dosing for 4 wk during the study.
Individual participant IF, RBC, and plasma EPA profiles
during the study are presented in Figure 3. Equivalent data for
DHA are available as Supplemental Figure 1. Comparative ω-
3 PUFA data are presented in Figure 4. In all cases, there was
<5 μg/mL EPA and DHA present in IF at baseline prior to oral
ω-3 PUFA dosing. Following the first dose of EPA/DHA with
a meal (median 2 h later), 4 participants exhibited an increase
in EPA and DHA content of ileal content (participants #2, #3,
#5, and #6), whereas the majority of participants (participants
#1, #4, and #7–11) displayed no clear increase in ileal ω-3
PUFA concentrations (Figure 3, Supplemental Figure 1). In every
case, a large rise in the concentration of EPA after initial ω-
3 PUFA capsules dosing (at visit 2) was accompanied by a
similar rise in DHA concentration (Figure 4). The acute rise
in EPA and DHA in a subgroup of 4 individuals was not
explained by a difference between the 2 groups of individuals
regarding the duration between dosing and IF sample collection
[mean = 2 h (range = 1–4 h) compared with 2 h (range =
1–3 h); P = 1.0, Mann–Whitney U test]. Overall, there was
no relation between the ileal EPA or DHA concentration and
duration between oral dosing and sample collection at visit 2
(ρ = 0.20, P = 0.57 and ρ = −0.17, P = 0.61, respectively;
Spearman rank correlation). The increase in EPA and DHA
content of IF in the subgroup of 4 participants was also not due
to more concentrated ileostomy output based on the osmolality
of the IF, which remained similar across the study visits and
was actually lower in the visit 2 samples that contained higher
concentrations of EPA and DHA (mean = 346 ± 21 compared
with 403 ± 45 mOsm/kg, P = 0.05; Student unpaired t test;
Supplemental Figure 1, Figure 3). We hypothesized that the
appearance of EPA and DHA in the ileum in 4 participants was
due to lower absorption in the proximal small intestine, which
might be associated with an absence of a peak in plasma ω-3
PUFA concentrations after oral dosing. However, there was no
difference in peak plasma EPA (mean = 61 ± 26 compared with
122 ± 97 μg/mL; P = 0.24; Student unpaired t test) or peak
plasma DHA (mean = 74 ± 35 compared with 90 ± 45 μg/mL;
P = 0.55) concentrations at visit 2, or the absolute difference in
concentration at visit 2 of EPA (16 ± 22 compared with 24 ± 18
μg/mL; P = 0.57) or DHA (−15 ± 84 compared with 29 ± 31
μg/mL; P = 0.27) compared with baseline values, between those
individuals with an increase in ileal EPA/DHA (participants
#2, #3, #5, and #6) and those with stable low concentrations
of ω-3 PUFAs (participants #1, #4, and #7–11) after first oral
supplementation (Supplemental Figure 1, Figure 3). However,
the lack of an acute peak plasma ω-3 PUFA response to oral
dosing is likely due to insufficient time between dosing and
plasma collection in this study (23).
In contrast to the rapid changes in EPA and DHA content
in IF after the first dose of ω-3 PUFA capsules in 4 participants,
there was no consistent change in concentration of the other
fatty acids that were measured at this time point (Supplemental
Table 1). Notably, there was no consistent increase in IF
docosapentaenoic acid (DPA) concentration after first dosing
(P = 0.21 for the difference between visit 1 and visit 2
concentrations; paired t test), even in those participants with
an acute rise in EPA and DHA concentrations at visit 2 (0.04 ±
0.03 μg/mL for participants #1, #4, and #7–11 compared with
0.29 ± 0.34 μg/mL for participants #2, #3, #5, and #6; P = 0.08;
Student unpaired t test), in keeping with direct transport of
orally administered EPA and DHA via the intestinal lumen
(Supplemental Table 1).
As expected, ∼4 wk of oral dosing with 4 g ω-3 PUFA
triglycerides led to a consistent increase in EPA and DHA
content in RBC membranes, with a mean EPA and DHA content
of RBCs at 4 wk of 3.3 ± 2.0% (baseline 1.6 ± 1.2%; P < 0.01;
paired t test) and 7.2 ± 2.7% (baseline 5.5 ± 3.2%; P = 0.05;
paired t test), respectively (Supplemental Figure 1, Figure 3),
which is consistent with previous data on RBC incorporation
of ω-3 PUFAs in different human populations (24, 25). The
RBC data were mirrored by a statistically significant increase
in plasma EPA and DHA concentrations in visit 3 samples
compared with baseline (visit 1) values (P = 0.01 and P < 0.01,
respectively; paired t test; Supplemental Figure 1, Figure 3). This
supports the notion that there was excellent capsule compliance
and that the physiology of ω-3 PUFA intestinal absorption in
participants with a temporary loop ileostomy is relevant to
individuals with an intact gastrointestinal tract.
Of note, in the 3 individuals for which there was a visit
3 IF sample (participants #2, #5, and #6), the increased
concentration of EPA and DHA in ileal content at visit 2 had
returned to concentrations (mean = 1.8 ± SD 1.5 and 2.3 ±
1.8 μg/mL, respectively) consistent with the other participants,
who did not have a visit 2 “peak” (9.0 ± 16.9 and 9.5 ± 18.7 ,
respectively; both P = 0.5, Student unpaired t test), despite the
fact that the time between oral dosing and sample collection
was similar between visit 2 and visit 3. This is consistent
with a possible adaptive response to oral ω-3 PUFA dosing
in individuals who initially exhibited increased distal intestinal
EPA and DHA bioavailability after first oral ω-3 PUFA dosing.
Overall, baseline (visit 1) IF EPA and DHA concentrations
increased from a mean of 1.00 ± 0.55 μg/mL (n = 10) and
0.90 ± 0.68 μg/mL, respectively, to 6.88 ± 14.28 μg/mL
(P = 0.025, Wilcoxon signed-rank test) and 7.34 ± 15.69
μg/mL (P = 0.008, Wilcoxon signed-rank test) after 28 d of oral
dosing (visit 3), which represents a mean fold increase of 6.0 ±
9.8 for EPA and 6.6 ± 9.6 for DHA in IF samples after oral
supplementation with ω-3 PUFAs. Excluding those individuals
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FIGURE 3 Ileostomy fluid and RBC membrane EPA concentrations in individual participants with a temporary ileostomy before and after ω-3
PUFA capsule dosing. The concentration of EPA in ileostomy fluid (IF) and the EPA content of RBC membranes at each time point for every
participant is shown. Corresponding data about the timing of sample collection for V2 and V3 samples in relation to ω-3 PUFA capsules dosing
(in hours), osmolality of IF (in milliosmoles per kilogram), and the plasma EPA concentration (micrograms per milliliter) for all visit samples are
presented below each figure panel. FA, fatty acid; IF, ileostomy fluid; V, visit.
who had a reversible peak in EPA and DHA concentrations at
visit 2 (participants #2, #3, #5, and #6), there was an increase
in IF EPA and DHA concentration at visit 3 compared with the
corresponding visit 2 value, but, in both cases, the difference
failed to reach statistical significance (P = 0.063 and 0.11
for EPA and DHA, respectively; Wilcoxon signed-rank test).
Consistent with the visit 2 data, there was also no relation
between the ileal EPA or DHA concentration and duration
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FIGURE 4 The distribution of ileostomy fluid EPA and DHA values
in individual participants with a temporary ileostomy. Individual data
points are presented for both EPA and DHA. The bar denotes the
median value for each group. Dotted lines join EPA and DHA values
from those individuals with higher ω-3 PUFA concentrations at V2 and
V3. In each case, there was a consistently high concentration of both
EPA and DHA in keeping with the 1:1 ratio of EPA and DHA in the
oral ω-3 PUFA capsule intervention. FA, fatty acid; IF, ileostomy fluid;
V, visit.
between oral dosing and sample collection at visit 3 (ρ = 0.36,
P = 0.30 and ρ = −0.26, P = 0.46, respectively; Spearman rank
correlation).
The human small intestinal microbiota has been investigated
inadequately in comparison with the colonic (fecal) microbiota,
primarily related to the relative difficulty with which human
small intestinal luminal samples can be obtained (26). There-
fore, we took the opportunity to investigate the effects of oral
ω-3 PUFA supplementation on the small intestinal microbiome
in individuals with a temporary ileostomy.
Consistent with previous reports describing the bacterial
structure of ileal fluid, we found that the dominant genera
in ileal content prior to ω-3 PUFA supplementation consisted
of Bacteroides, Clostridium, Escherichia/Shigella, Turcibacter,
Haemophilus, and Streptococcus (Supplemental Figure 2,
Figure 5A) (25). QIIME2 combined the 2 Enterobacteriaceae
genera Escherichia and Shigella as a single genus category, which
was then used in MEGAN for further analysis. The top 10
genera made up >90% of the total operational taxonomic
units (OTUs) measured (Figure 5A). As expected, there was
wide variation in the ileal microbiome between individuals
at baseline (visit 1) demonstrated by Bray–Curtis principal
component analysis (PCoA; SupplementalFigure 2, Figure 5B).
Consistent with the dynamic nature of small intestinal content
and its microbiota, there were large intraparticipant differences
between the baseline IF sample (visit 1) and the corresponding
sample taken a few hours after first oral dosing with ω-3 PUFA
capsules (visit 2; Figure 5B). There was no significant difference
across the visit profiles (PERMANOVA, P = 0.93) with
variability between the participants being the only significant
variable (PERMANOVA, P = 0.001). Importantly, there was
no discernible difference in the relation between visit 1 and
visit 2 profiles between individuals who displayed an EPA
and DHA peak after first oral dosing (participants #2, #3,
#5, and #6) and those that did not (participants #1, #4, and
#7–11). This suggests that an acute increase in luminal EPA
and DHA concentration does not acutely change the ileal
microbiome in a consistent manner, over and above natural,
dynamic variability in ileal content over short periods of time
(Figure 5B). Consistent with this notion, the ileal microbiome
in the participants who displayed a visit 2 EPA and DHA peak
did not return consistently to a microbiome profile at visit 3
more closely resembling visit 1, even though IF EPA and DHA
concentrations consistently reduced to concentrations of the
same order of magnitude as visit 1 values in all participants
(Figure 5B).
In keeping with the large intra- and interindividual variabil-
ity in the ileal microbiome demonstrated by PCoA, there were
major shifts in abundance of the top 10 genera between the
3 samples, before (visit 1), during (visit 2), and immediately
after (visit 3) ω-3 PUFA dosing (Figure 5A). Changes in the
top 15 most abundant genera after the first dose of ω-3 PUFA
capsules (difference between visit 2 and visit 1) and after oral ω-
3 PUFA supplementation therapy for 28 d (difference between
visit 3 and visit 1) in each of the participants are represented
in Supplemental Figure 2. There was no consistent relation
observed between the difference in genus abundance associated
with first dosing with ω-3 PUFA capsules and that associated
with dosing for 28 d in any of the participants (Supplemental
Figure 2). There was also no evidence that changes in taxa
abundance at each of the 2 time points compared with baseline
were common across all the participants, although Bacteroides
and Veillonella abundance was static or increased in 8 of the 11
participants across both time points (Supplemental Figure 2).
Next, we explored the relation between genus abundance in
ileal content and ileal fluid fatty acid concentrations in each
participant. Eight of the top 35 genera had zero OTU abundance
in >5 samples. Therefore, we decided to exclude those taxa from
correlation analysis. There was a strong correlation between
the increase in EPA and DHA (and the direct EPA elongation
metabolite DPA) concentration in ileal fluid obtained after 28 d
dosing with ω-3 PUFAs (visit 3) compared with baseline (visit
1) and the change in abundance of several genera between
the same time points (Figure 6). Higher concentrations of
the supplemented ω-3 PUFAs in ileal fluid were associated
with an increased abundance of Bacteroides, which was not
observed for the other fatty acids including the other ω-3
PUFA, 18:3ω-3 α-linolenic acid (LNA; Figure 6). Conversely,
increased concentrations of EPA and DHA in ileal fluid were
associated with reduced abundance of 2 genera (Granulicatella
and Actinomyces), which was not shared by the other fatty
acids that were measured (Figure 6). In contrast, changes in
luminal concentrations of the shorter-chain-length ω-3 PUFA
that was not supplemented (LNA) correlated with different
genera in ileal fluid including Sutterella (Figure 6). Importantly,
no significant correlations were observed between the change
in bacterial abundance between baseline to visit 3 and fatty
acid concentrations in RBC membranes (Figure 6), suggesting
that the relations between altered abundance of specific genera
and concentrations of supplemented ω-3 PUFAs are specific
to the local ileal environment, not an increase in systemic
concentrations of EPA and/or DHA. A similar analysis was also
performed to explore the relation between genus abundance
in ileal content and ileal fluid fatty acid concentrations after
acute dosing at visit 2 (after the first capsules dose). In contrast
to the relations observed between the change in EPA and
DHA concentrations in the ileum and bacterial abundance
after oral dosing for 28 d (Figure 6), there was no evidence
of an association between the acute change in either EPA or
DHA concentrations and bacterial abundance in ileal fluid
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A
B
FIGURE 5 Analysis of the ileal microbiome before, during, and at the end of oral ω-3 PUFA supplementation in patients with a temporary
ileostomy. (A) The 20 most abundant bacterial genera in ileostomy fluid at baseline, as well as during and after oral dosing with ω-3 PUFAs for
28 d. Columns represent the mean relative OTU counts for all participants who provided the relevant sample at baseline (V1; red), after the first
dose of ω-3 PUFA capsules (V2; green) and after 28 d of oral ω-3 PUFA dosing (V3; blue). Bars represent the SEs of the mean. (B) Bray–Curtis
PCoA of the ileal microbiome before and after oral dosing with ω-3 PUFAs. Each participant is represented by a symbol of different color and
shape, as well as a participant number label. Blue lines join data points at baseline (V1), after the first dose of ω-3 PUFA capsules (V2), and
after the last dose of ω-3 PUFA capsules (V3) after 28 d of dosing with oral ω-3 PUFA capsules. OTU, operational taxonomic unit; PC, principal
component; PCoA, principal component analysis; V, visit.
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FIGURE 6 Correlation matrices for the difference in bacterial genus abundance and the difference in absolute ileal fluid fatty acid concentrations
(and RBC percentage content) between baseline (V1) and after 28 d of treatment with ω-3 PUFA capsules (V3) in patients with a temporary
ileostomy. Blue denotes a positive correlation. Red denotes a negative correlation. The strength of the Pearson correlation is denoted by the
colour intensity (side-bar scale). Statistically significant (P < 0.05) relations are signified by an asterisk with the actual r2 value. AA, arachidonic
acid; DPA, ω-3 docosapentaenoic acid; LA, linoleic acid; LNA, α-linolenic acid; OA, oleic acid; PA, palmitic acid; SA, stearic acid, V, visit.
(Supplemental Figure 3). This confirms that acute changes in
ileal ω-3 PUFA concentrations do not alter the ileal microbiome,
unlike oral supplementation with EPA and DHA for several
weeks. There were 4 isolated statistically significant negative
correlations between the difference in RBC content of fatty
acids, including oleic acid, and 3 bacterial genera after first
dosing, which lack biological plausibility given the kinetics of
fatty acid incorporation into RBC membranes and could have
resulted from multiple testing (Supplemental Figure 3).
Discussion
We report that twice daily oral supplementation with EPA and
DHA for 28 d (providing the equivalent of 1 g EPA free fatty
acid and 1 g DHA free fatty acid per day) leads to an increase
in ileal fluid EPA and DHA content, which is associated with
an increased abundance of Bacteroides and a decrease in other
bacterial genera that is observed despite high variability in the
distal small bowel microbiota between individuals and over
time.
Assuming a 24-h ileostomy output of 1000 mL, one can
estimate that an approximate EPA and DHA concentration
of 7 μg/mL in ileal fluid after 28 d dosing could equate to
as little as 1% of the orally administered dose appearing in
the ileum (and hence the proximal colon) assuming that all
luminal ω-3 PUFAs derive directly from oral administration,
rather than indirectly from small intestinal mucosa. This is a
similar magnitude to the proportion of ω-3 PUFAs recovered in
ileal fluid after oral administration of a smaller dose (<300 mg)
of ω-3 PUFAs (<1%) in a previous study (9). Consistent
with equal dosing with EPA and DHA in this study, similar
changes in luminal concentrations of EPA and DHA were
measured in each participant. As expected, there were no other
significant changes in the fatty acid profile of ileal fluid after
oral administration of pure EPA and DHA. Knowledge that
microgram per milliliter concentrations of EPA and DHA are
generated in the distal small intestine after oral dosing will
inform ex vivo experiments investigating EPA- and DHA-
derived bioactive lipid mediator production and activity on the
gut microbiota, including proresolving oxylipins such as E- and
D-type resolvins (27).
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We designed our study so that we compared ileal fluid
samples after the first dose of ω-3 PUFA capsules and after
the last dose of capsules (after supplementation for 28 d) at
an equivalent time after ingestion. This allowed us to estimate
the contribution of direct oral delivery of ω-3 PUFAs to ileal
ω-3 PUFA bioavailability (visit 2 concentrations in previously
ω-3 PUFA–“naïve” ileal fluid) compared with delivery of ω-3
PUFAs to the ileal lumen via the ileal mucosa—hypothesized
to occur only after medium-term (28-d) dosing (visit 3) that
produces increased tissue (mucosal) ω-3 PUFA concentrations.
The acute rise in EPA and DHA concentrations in ileal fluid,
which was demonstrated in 4 individuals, confounds the
comparison of visit 2 and visit 3 ω-3 PUFA concentrations
in all participants. However, exclusion of this subgroup of
individuals from this analysis confirmed that, although ileal
fluid EPA and DHA concentrations were higher after medium-
term oral dosing than before supplementation, there was no
consistent or statistically significant increase in ileal ω-3 PUFA
bioavailability after oral supplementation for 28 d compared
with that after the first oral dose. This implies that ω-3
PUFAs originating from the ileal mucosa (perhaps through shed
enterocytes) are likely to make only a small contribution to ileal
(and hence proximal colonic) ω-3 PUFA bioavailability during
prolonged dosing. We accept that other factors could explain
differences between ileal fluid EPA and DHA concentrations
after short- and longer-term oral supplementation, including
changes to proximal small intestinal digestion and absorption
of ω-3 PUFAs (as triglycerides) during consistent ω-3 PUFA use.
The only experimental protocol that could directly address the
precise contribution of luminal delivery compared with release
from the mucosal surface to intestinal bioavailability in humans
would be measurement of EPA and DHA concentrations in the
intestinal lumen after parenteral administration of labeled ω-3
PUFAs.
An unexpected finding was the relatively high concentrations
of EPA and DHA found in ileal fluid only a short time after
first dosing with oral ω-3 PUFA capsules in 4 of the 11 study
participants. We hypothesize that these individuals did not
absorb orally administered ω-3 PUFAs to the same degree
as the other participants. The reduction in EPA and DHA
concentrations in ileal fluid at a similar time after dosing
with capsules 28 d later suggests that physiological adaptation
could then have occurred in these individuals. However, we
cannot exclude that variability in the size or composition of
the meal taken with the first dose of capsules explains the
acute rise in luminal EPA and DHA concentrations in this
subgroup. A larger study is required to quantify with greater
precision the proportion of individuals that display an acute
rise in intestinal ω-3 PUFA concentrations at the start of oral
supplementation.
The ileal microbiome data represent a significant addition
to the limited literature on the small intestinal microbiota.
Historical studies using a variety of techniques have previously
reported that Bacteroides and Clostridium genera are prevalent
in the small intestine, which is consistent with our findings (28).
Wide variability in the ileal microbiome between individuals
and over time is consistent with current understanding of the
dynamic nature of the small intestinal microbiota that appears
reactive to nutrient flow (29). Importantly, we saw no consistent
acute changes in the ileal microbiome during acute dosing,
particularly in those individuals who generated relatively high
EPA and DHA concentrations after first dosing. There was,
however, a consistent relation between the increase in EPA and
DHA content of ileal fluid and abundance of certain bacterial
genera after 28 d of dosing. Of note, there was a strong relation
between the increase in EPA, DPA, and DHA (but not LNA)
concentrations and increased abundance of Bacteroides in ileal
content. The Bacteroides genus contains many SCFA-producing
species (30), which is compatible with the effect of the same
daily dose of ω-3 PUFAs on SCFA-producing bacterial taxa
in fecal samples from a healthy volunteer study (3) and more
recent findings from a study of low-dose EPA (165 mg daily)
and DHA (110 mg daily) administration on fecal Bacteroides
abundance in healthy volunteers (8). The latter study also
reported that ω-3 PUFA supplementation was associated with
increased plasma concentrations of SCFAs (8). The relevance of
the negative correlation between an increase in EPA and DHA
concentrations and abundance of other less prominent genera
such as Actinomyces remains unclear.
Although our data demonstrate an association between
intestinal luminal concentrations of ω-3 PUFAs and abundance
of some bacterial genera, we cannot infer a causal relation
between ω-3 PUFA exposure and an altered ileal microbiome.
Data from transgenic Fat-1 and Fat-2 mouse models suggest
that alterations in the intestinal tissue content of ω-3 and ω-6
PUFAs modulate the fecal microbiome independently of changes
in dietary PUFA intake, perhaps via a mechanism involving
epithelial intestinal alkaline phosphatase expression (31, 32).
Strengths of this human intervention study include use of
an ω-3 PUFA capsule formulation of pure EPA and DHA
mimicking clinical trial dosing, rather than a complex PUFA
mixture, thus allowing interpretation of the effects of oral
supplementation on small intestinal bioavailability of the 2
main marine-derived ω-3 PUFAs without confounding by other
fatty acids. Completion of a protocol whereby ileal fluid and
blood sampling occurred at a similar time after dosing at the
beginning and end of the intervention period was challenging,
but has provided significant insight into changes in intestinal
physiology and ω-3 PUFA bioavailability over a 28-d period
that might have been masked if the relation with oral dosing
had been less precise.
Several limitations in study design deserve attention. The
size of the study was restricted by the acceptability of
the experimental protocol that offered no personal benefit
and mandated timed biological sampling. We accept that
the presence of a temporary loop ileostomy alters small
intestinal physiology, particularly increased small intestinal
transit, which might explain the rapid (few hours) appearance
of orally delivered EPA and DHA in ileostomy output in some
participants. We deliberately stipulated a minimum period (2
mo) for any participant to have had a temporary ileostomy (in
the majority, it was substantially longer) so that changes in small
intestinal function during the 4-wk duration of the study were
unlikely and would not be likely to explain differences in ω-
3 PUFA bioavailability between acute (first dose) and chronic
(after supplementation for 28 d) oral dosing. It should also be
emphasized that IF can only be considered a proxy for luminal
fluid in an intact terminal ileum. This is particularly relevant
to the microbiome analysis, which might be confounded by
contamination from the local stoma environment (26). The
similarity in microbiome profile between our study of IF
and other studies of ileal fluid and ileal mucosa sampled at
ileocolonoscopy suggests that IF is a reasonable compromise
to study the ileal microbiome without exposing study subjects
to an invasive and unpleasant colonoscopic procedure (28). We
did not collect information on antibiotic use in the preceding 6
mo. We also acknowledge that we did not standardize dietary
intake or physical activity levels prior to each of the study visits
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(in order to increase study acceptability for participants) so
we cannot exclude that differences in gastrointestinal transit
time and absorption related to meal composition contributed
in part to the results. Finally, we recognize the risk of
type 1 statistical error from the large number of analyses
performed.
In summary, we report that oral dosing with ω-3 PUFAs
for 28 d leads to an increase in EPA and DHA bioavailability
in IF, relevant to therapeutic use of ω-3 PUFAs for ileocolonic
diseases. The ileal microbiome is highly variable between and
within individuals. However, a relation between abundance
of Bacteroides and luminal EPA and DHA concentration was
evident and is consistent with the emerging hypothesis that ω-3
PUFA use drives increased luminal SCFA exposure (3, 8).
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